Casals-Stenzel J
Eur J Pharmacol. 1987 Mar 17;135(2):117-22. doi: 10.1016/0014-2999(87)90602-9.
WEB 2086, a novel specific platelet activating factor (PAF) antagonist derived from triazolodiazepines, inhibited in a dose-related manner the hypotensive and lethal effect of PAF as well as of E. coli endotoxin in the rat. The hypotension induced by endotoxin (15 mg/kg i.v.) or PAF (30 ng/(kg X min) i.v.) in anaesthetized rats was prevented by oral (1-10 mg/kg) and inhibited or reversed by i.v. (0.1-5.0 mg/kg or 0.1-1.0 mg/kg) doses of WEB 2086. Similar oral and i.v. doses of WEB 2086 protected conscious rats from PAF (15 micrograms/kg i.v.)- and endotoxin (7.5 mg/kg i.v.)-induced death. The results obtained with WEB 2086 confirm that PAF has an important role in the pathophysiology of endotoxin shock. This compound may have a therapeutic effect in human septic shock.
WEB 2086是一种源自三唑二氮杂卓的新型特异性血小板活化因子(PAF)拮抗剂,它以剂量相关的方式抑制了PAF以及大肠杆菌内毒素对大鼠的降压和致死作用。在麻醉大鼠中,静脉注射内毒素(15毫克/千克)或PAF(30纳克/(千克×分钟))所诱导的低血压,可通过口服(1 - 10毫克/千克)预防,并被静脉注射(0.1 - 5.0毫克/千克或0.1 - 1.0毫克/千克)剂量的WEB 2086抑制或逆转。类似的口服和静脉注射剂量的WEB 2086可保护清醒大鼠免于PAF(15微克/千克静脉注射)和内毒素(7.5毫克/千克静脉注射)诱导的死亡。用WEB 2086获得的结果证实PAF在内毒素休克的病理生理学中起重要作用。这种化合物可能对人类感染性休克有治疗作用。